Life Science Investing Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
Life Science Investing Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
Life Science Investing CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
